Psilocybin Response

Brain Imaging May Help Predict Psilocybin Response

November 18, 2026

Brain imaging could eventually help researchers identify who is more likely to benefit from psilocybin for depression. A new preprint, Rapid Antidepressant Effects Of Psilocybin Without Increased SV2A Binding, reports an exploratory association between a pretreatment imaging measure and subsequent symptom improvement [1].

The study included 35 participants with moderate-to-severe recurrent major depressive disorder. Antidepressant improvement occurred without a detectable group-level increase in the imaging marker, separating two questions: what changes after treatment, and what might predict benefit beforehand.

Predicting Benefit Remains An Unresolved Challenge

Psilocybin trials typically assess outcomes through changes in depressive symptoms. Researchers are also investigating biological measures that might explain differences in treatment response.

A useful predictive marker would need to provide reliable information beyond an initial clinical assessment. This study examined whether a PET measure associated with synaptic density might offer such information.

The findings remain preliminary. The report was posted on medRxiv on November 8, 2026, and has not undergone peer review.

Scanning Before And After Treatment

Participants were randomized to a single dose of 25 mg psilocybin or 100 mg niacin placebo. Both groups received psychotherapeutic support.

Researchers performed positron emission tomography, or PET, two to seven days before dosing and again approximately 15 days afterward, within a seven-day window on either side.

The scans used the radioactive tracer [¹¹C]UCB-J, which binds to synaptic vesicle glycoprotein 2A, or SV2A. This protein is found in nerve terminals and provides an indirect marker associated with synaptic density.

The preregistered imaging substudy examined the hippocampus and frontal cortex. Its placebo comparison helped distinguish treatment-associated changes from changes occurring over time.

Baseline Binding Was Associated With Psilocybin Response

Despite significant clinical improvement in the psilocybin group, researchers found no evidence of increased SV2A binding relative to niacin in the regions examined.

A separate analysis produced the finding behind the potential prediction signal: higher baseline total distribution volume, known as Vₜ, was associated with greater subsequent improvement in the psilocybin group.

That association survived false discovery rate correction at Days 8 and 15, two of three preregistered assessment timepoints. This correction helps account for the increased likelihood of chance findings when researchers conduct multiple statistical tests.

However, an association within a small study does not establish an accurate prediction tool for individual patients.

Improvement Did Not Require A Detectable PET Increase

Changes in Vₜ initially showed associations with clinical improvement. Those relationships weakened after adjustment for baseline binding and initial depression severity, and did not survive correction for multiple testing.

The more consistent signal therefore concerned pretreatment binding, rather than an increase following treatment.

Importantly, the absence of a detectable group-level increase does not establish that psilocybin produced no synaptic changes. PET measurements reflect a particular biological target, in selected regions, during a defined observation window.

Synaptic Density Captures Only Part Of Plasticity

Neuroplasticity includes changes in connection strength, organization, and function. An SV2A scan does not directly capture every form of adaptation or count individual synapses.

Related peer-reviewed research in 15 healthy participants likewise found no statistically significant overall increase in SV2A binding after psilocybin. Exploratory differences associated with the dosing environment underscored the complexity of interpreting these measurements [2].

The new study adds a depression sample and randomized placebo comparison, making it particularly relevant to treatment research.

A Candidate Marker Needs Independent Validation

For clinicians, the immediate implication is a research priority. Baseline SV2A binding warrants further investigation as a possible response marker, but the study does not establish a threshold for selecting patients.

Larger, independent studies would need to test predictive accuracy, reproducibility, and whether imaging improves decisions beyond existing clinical information.

Brain imaging may help clarify differences in psilocybin response. For now, the finding supports testing a candidate biomarker while avoiding the assumption that antidepressant benefit must coincide with a measurable increase in this synaptic marker.

Citations

  1. Yngwe H, Plavén-Sigray P, Andersson M, et al. Rapid antidepressant effects of psilocybin without increased SV2A binding: baseline binding predicts response. medRxiv. Posted November 8, 2026. Preprint.
  2. Johansen A, Plavén-Sigray P, Madsen MK, et al. Psilocybin’s effect on human brain synaptic plasticity. Translational Psychiatry. 2026;16:544.
Photo of author

IPN Team

Read more topics from the Interventional Psychiatry News & Subscribe to our Newsletter

Join 11,000+ Interventional Psychiatry Providers & Industry Insiders
Get the latest news, research, clinical breakthroughs, and industry updates delivered to your inbox.

Subscribe Free → https://interventionalpsychiatry.org/newsletter/

Follow Interventional Psychiatry News